| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. | Chief Scientific Officer | Common Stock | 31K | $259K | $8.37 | Dec 5, 2023 | Direct |
| iTeos Therapeutics, Inc. | Chief Scientific Officer | Stock Option (Right to Buy) | 154K | Mar 7, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ITOS | iTeos Therapeutics, Inc. | Mar 7, 2024 | 1 | $0 | 4 | Mar 8, 2024 | Chief Scientific Officer |
| ITOS | iTeos Therapeutics, Inc. | Dec 5, 2023 | 1 | $0 | 4 | Dec 7, 2023 | Chief Scientific Officer |
| ITOS | iTeos Therapeutics, Inc. | Mar 9, 2023 | 1 | $0 | 4 | Mar 10, 2023 | Chief Scientific Officer |
| ITOS | iTeos Therapeutics, Inc. | Mar 11, 2022 | 1 | $0 | 4 | Mar 14, 2022 | Chief Scientific Officer |
| ITOS | iTeos Therapeutics, Inc. | Mar 1, 2022 | 3 | -$325K | 4 | Mar 2, 2022 | Chief Scientific Officer |
| ITOS | iTeos Therapeutics, Inc. | Jun 8, 2021 | 3 | -$125K | 4 | Jun 10, 2021 | VP, Research and Development |
| ITOS | iTeos Therapeutics, Inc. | Jun 1, 2021 | 6 | -$126K | 4 | Jun 3, 2021 | VP, Research and Development |
| ITOS | iTeos Therapeutics, Inc. | May 24, 2021 | 3 | -$140K | 4/A | Jun 3, 2021 | VP, Research and Development |
| ITOS | iTeos Therapeutics, Inc. | May 17, 2021 | 5 | -$162K | 4 | May 19, 2021 | VP, Research and Development |